TEL
AVIV, Israel, Oct. 28,
2022 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibro-inflammatory diseases with high unmet need, today
announced that the company will participate in several scientific
conferences in November.
AASLD - The Liver
Meeting® 2022
Date: November 4-8,
2022
Venue: Walter E. Washington Convention Center, Washington, DC
Format: Poster presentation: CCL24 Blockade
Attenuates Biliary Inflammation by Interfering with Monocyte and
Neutrophil Recruitment, Abstract ID:3314
Time: November 6, 2002,
1:00 pm ET, Poster Hall
Presenter: Ilan Vaknin, PhD,
Vice President of R&D, Chemomab
Information:
https://www.aasld.org/the-liver-meeting
A copy of the poster will be available at the R&D section of
Chemomab's website (www.chemomab.com).
Union World Conference on Lung
Health 2022
Date: November 8-11,
2022
Venue: Virtual
Format: Oral presentation: CM-101 Treatment in Patients
with Lung Damage Derived from Covid-19 Reduced
Inflammatory and Fibrotic Biomarkers
Session:
LBCOV: The Union Late-Breaker session on
COVID-19
Time: November 9,
2022, 12:30-13:50 CET
Presenter: Adi Mor, PhD, Co-Founder & Chief
Scientific Officer, Chemomab
Information: https://conf2022.theunion.org/
A copy of the presentation will be available at the R&D section
of Chemomab's website (www.chemomab.com).
6th Annual
Anti-Fibrotic Drug Development (AFDD) Summit
Date: November 9-11, 2022
Venue: Crowne Plaza Woburn, Woburn, MA
Format: Oral presentation: Crossing the Divide:
Leveraging Fibrosis-Inflammatory Biomarkers to Inform Clinical
Trial Design
Session: lluminating the Latest
in Fibrotic Biomarkers Across Indications to Harness
Predictive and Progressive Biomarkers in Clinical
Development
Time:November
10, 2022, 11:00 am ET
Presenter: Adi Mor, PhD, Co-Founder & Chief
Scientific Officer, Chemomab
Information: https://afdd-summit.com/
A copy of the presentation will be available at the R&D section
of Chemomab's website (www.chemomab.com).
About Chemomab Therapeutics
Ltd.
Chemomab is a clinical-stage biotechnology company focusing on
the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to begin in late 2022. For more information, visit
chemomab.com.
Contacts:
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President,
Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara@chemomab.com
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1 917-734-7387
ir@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-upcoming-scientific-conferences-301662139.html
SOURCE Chemomab Therapeutics, Ltd.